Literature DB >> 6249436

A classification of opiate receptors that mediate antinociception in animals.

M B Tyers.   

Abstract

1 To investigate the opiate receptors that mediate antinociception, the activity profiles of opioid analgesic drugs have been determined against different nociceptive stimuli in the mouse and rat. 2 In tests that employ heat as the nociceptive stimulus, mu-opiate receptor agonists, such as morphine, pethidine and dextropropoxyphene, had steep and parallel dose-response curves and were capable of achieving maximum effects. In addition, the antinociceptive potency ratios of these drugs in heat tests were similar to those for analgesia in man. 3 The kappa-agonists, such as ethylketazocine, nalorphine, Mr2034 and pentazocine, were essentially inactive against heat nociception except at doses that caused sedation and motor incapacitation. 4 In the writhing and paw pressure tests both mu- and kappa-agonists produced steep and parallel dose-response curves. 5 It is concluded that both mu- and kappa-opiate receptors mediate antinociception in animals and that the interactions of analgesic drugs with these receptors may be classified in terms of their antinociceptive activities against qualitatively different nociceptive stimuli.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249436      PMCID: PMC2044269          DOI: 10.1111/j.1476-5381.1980.tb07041.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Antinociceptive activitiy of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats.

Authors:  R D Sewell; P S Spencer
Journal:  Neuropharmacology       Date:  1976-11       Impact factor: 5.250

2.  Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure.

Authors:  J P O'Callaghan; S G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  1975-03       Impact factor: 4.030

3.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

4.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey.

Authors:  M Hutchinson; H W Kosterlitz; F M Leslie; A A Waterfield
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

6.  Inhibition of writhing by narcotic antagonists.

Authors:  J Pearl; L S Harris
Journal:  J Pharmacol Exp Ther       Date:  1966-11       Impact factor: 4.030

7.  Measurement of the analgesic efficacy and potency of pentazocine by the D'Amour and Smith method.

Authors:  W D Gray; A C Osterberg; T J Scuto
Journal:  J Pharmacol Exp Ther       Date:  1970-03       Impact factor: 4.030

8.  Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics.

Authors:  J Hughes; H W Kosterlitz; F M Leslie
Journal:  Br J Pharmacol       Date:  1975-03       Impact factor: 8.739

9.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

10.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

View more
  53 in total

1.  The acute antinociceptive effect of HBO₂ is mediated by a NO-cyclic GMP-PKG-KATP channel pathway in mice.

Authors:  Lindsay P Quock; Yao Zhang; Eunhee Chung; Yusuke Ohgami; Donald Y Shirachi; Raymond M Quock
Journal:  Brain Res       Date:  2010-10-25       Impact factor: 3.252

2.  Pharmacological profile of PD 117302, a selective kappa-opioid agonist.

Authors:  G E Leighton; M A Johnson; K G Meecham; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

3.  AMPAkines and morphine provide complementary analgesia.

Authors:  Yongjun Sun; Kevin Liu; Erik Martinez; Jahrane Dale; Dong Huang; Jing Wang
Journal:  Behav Brain Res       Date:  2017-07-19       Impact factor: 3.332

4.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

5.  Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

Review 6.  To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine.

Authors:  T Anthony Anderson; Aurora N A Quaye; E Nalan Ward; Timothy E Wilens; Paul E Hilliard; Chad M Brummett
Journal:  Anesthesiology       Date:  2017-06       Impact factor: 7.892

7.  Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

8.  Role of histamine in rodent antinociception.

Authors:  P Malmberg-Aiello; C Lamberti; C Ghelardini; A Giotti; A Bartolini
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

9.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

10.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.